DekaBank Deutsche Girozentrale’s G1 Therapeutics, Inc. Common Stock GTHX Stock Holding History

DekaBank Deutsche Girozentrale’s Portfolio GTHX Stock Details GTHX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-46,900	Closed	-$695K	–	1497
2021 Q3	$695K	Hold	46,900	–	–	﹤0.01%	980
2021 Q2	$1.06M	Hold	46,900	–	–	﹤0.01%	892
2021 Q1	$1.07M	Hold	46,900	–	–	﹤0.01%	882
2020 Q4	$845K	Buy	46,900 +34,000	+264%	+$508K	﹤0.01%	911
2020 Q3	$150K	Buy	+12,900	New	+$213K	﹤0.01%	1088
2019 Q3	–	Sell	-18,800	Closed	-$585K	–	1143
2019 Q2	$585K	Buy	18,800 +7,300	+63%	+$154K	﹤0.01%	900
2019 Q1	$691K	Buy	11,500 +2,100	+22%	+$39.8K	﹤0.01%	848
2018 Q4	$180K	Sell	9,400 -2,100	-18%	-$78.7K	﹤0.01%	982
2018 Q3	$691K	Sell	11,500 -300	-3%	-$16.4K	﹤0.01%	867
2018 Q2	$504K	Hold	11,800	–	–	﹤0.01%	903
2018 Q1	$423K	Buy	+11,800	New	+$315K	﹤0.01%	896

Other funds holding GTHX

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

LOAMS

Lombard Odier Asset Management (Switzerland) Petit-Lancy, Switzerland $2.63B AUM 31.52% 1-Year Est. Return

MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

DekaBank Deutsche Girozentrale's GTHX Position: Q4 2021 in Review

DekaBank Deutsche Girozentrale sold out of G1 Therapeutics, Inc. Common Stock (GTHX) in Q4 2021, closing a stake of 46,900 shares — an estimated $695K sold.

DekaBank Deutsche Girozentrale first reported a position in GTHX in Q1 2018 and held it in 11 quarters. The position peaked at $1.07M in Q1 2021. 108 funds tracked by Wall St. Rank hold GTHX as of Q4 2021.

DekaBank Deutsche Girozentrale reported no remaining G1 Therapeutics, Inc. Common Stock position as of Q4 2021 after selling out during the quarter.
DekaBank Deutsche Girozentrale sold 46,900 G1 Therapeutics, Inc. Common Stock shares in Q4 2021, an estimated $695K.
DekaBank Deutsche Girozentrale first reported a position in G1 Therapeutics, Inc. Common Stock in Q1 2018 and held it in 11 quarters.
DekaBank Deutsche Girozentrale's G1 Therapeutics, Inc. Common Stock position peaked at $1.07M in Q1 2021.
108 funds tracked by Wall St. Rank held G1 Therapeutics, Inc. Common Stock as of Q4 2021.

Based on DekaBank Deutsche Girozentrale's 13F filing for Q4 2021, filed 2 Feb 2022.